Max is a Senior Associate on the Life Sciences team, and focuses on identifying new investment opportunities.
Max joined Frazier Healthcare Partners in 2019 and focuses on identifying and evaluating new investment opportunities in the life sciences sector. He also currently serves as Vice President, Acquisitions for Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC). Max has been involved in multiple Frazier Life Sciences public investments since joining the firm, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Iveric Bio (NASDAQ: ISEE).
Prior to joining Frazier, Max founded and managed a small investment fund focused on public biotech equities as well as the development of mechanical systems for use in other asset classes, with an emphasis on risk management. Previously, Max was a senior business analyst at Zymergen where he worked on internal strategy initiatives based around the company’s proprietary high-throughput genetic engineering methodology. Max began his career in New York as an investment banking analyst in the healthcare mergers & acquisitions group at Evercore Partners, focusing on biotech and medtech companies.
Max received his M.D. from the Weill Cornell Medical College of Cornell University, where he was awarded the Siegel Family Student Prize, and his B.A. in physics and biochemistry from Bowdoin College.
Weill Cornell Medical College of Cornell University (M.D.)
Bowdoin College (B.A.)